CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

KAZIA THERAPEUTICS LTD

KZIA
$160MMicro Cap

Next catalyst

Phase 2December 2026

PAXALISIB

Primary Central Nervous System Lymphoma

Get an email about KZIA's next catalysts

Track KAZIA THERAPEUTICS (KZIA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

No other upcoming event in our data.

Catalyst Timeline

1 upcoming, 1 past

Phase 2Next

PAXALISIB Phase 2 Est. Readout

December 2026~PAXALISIB25

Estimated primary completion for PAXALISIB trial (NCT04906096) in Primary Central Nervous System Lymphoma. Topline data typically follows completion by weeks to months.

Source

How KZIA's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical PreparationsπŸ‡ΊπŸ‡ΈNorth AmericaSYDNEY NSW6 employees

Frequently asked questions

What is in KAZIA THERAPEUTICS LTD's drug pipeline?β†’

CatalystAlert tracks 10 drug candidates in KAZIA THERAPEUTICS LTD's (KZIA) pipeline across Phase 3, Phase 2. Its lead program is PAXALISIB (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is KAZIA THERAPEUTICS LTD's next FDA catalyst?β†’

KAZIA THERAPEUTICS LTD's (KZIA) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track KZIA biotech catalysts?β†’

Add KZIA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow KAZIA THERAPEUTICS LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply